Erythemal episodes during phototherapy can be painful, limit efficacy due to premature discontinuation of treatment and may contribute to chronic cutaneous damage. Many patients receiving phototherapy take photosensitive medications. Stern et al., investigated 1,125 patients receiving maintenance psoralen‐ultraviolet A photochemotherapy (PUVA) for psoriasis and did not detect a significant difference in risk of erythemal episodes between those receiving photosensitising medication compared with those who were not1. However, amongst older (≥45 years‐old) users of photoactive drugs, 10% discontinued PUVA for at least a month because of “burns” compared with only 5% on “non‐users”.
Harrop, G. A., Dawe, R., & Ibbotson, S. (2018). Are photosensitizing medications associated with increased risk of important erythemal reactions during ultraviolet B phototherapy? British Journal of Dermatology, 179(5), 1184-1185. https://doi.org/10.1111/bjd.16800